CONTEXT: Alterations of protein turnover may contribute to the progressive decline of muscle mass with aging. OBJECTIVE: Our objective was to examine the effects of near-physiological recombinant human GH and/or testosterone (T) administration to older men on whole body protein kinetics and muscle gene expression. DESIGN, SETTINGS, AND PARTICIPANTS: A 6-month randomized, double-blind, placebo-controlled trial in 21 healthy elderly men aged 65-75 yr, was performed. Participants were randomized to receive placebo GH and placebo T, rhGH and placebo T (GH), T and placebo GH (T), or rhGH and T (GHT). INTERVENTIONS: The leucine rate of appearance (index of proteolysis), nonoxidative leucine disposal rate (an index of protein synthesis), and leucine oxidation rate were measured with an infusion of l-[1-(13)C] leucine. Muscle biopsies for the measurement of gene expression were performed. Body composition and aerobic capacity (maximal oxygen capacity) were measured. RESULTS:Serum IGF-I levels increased significantly with GH and GHT (P < 0.001) compared with placebo. T increased significantly only in the T group (P = 0.028). Leucine rate of appearance and nonoxidative leucine disposal rate increased with GH (P = 0.015, P = 0.019) and GHT (P = 0.017, P = 0.02), but leucine oxidation did not change significantly in any treatment group. Midthigh muscle mass and maximal oxygen capacity increased (P < 0.04) with GHT only. Expression of muscle function genes did not change significantly, but the within-group comparisons revealed a significant increase of androgen receptor expression in the GHT group (P = 0.001). CONCLUSION: This study showed that 6-month treatment with low-dose GH alone or with T in healthy elderly men produces comparable increments in whole body protein turnover and protein synthesis.
RCT Entities:
CONTEXT: Alterations of protein turnover may contribute to the progressive decline of muscle mass with aging. OBJECTIVE: Our objective was to examine the effects of near-physiological recombinant human GH and/or testosterone (T) administration to older men on whole body protein kinetics and muscle gene expression. DESIGN, SETTINGS, AND PARTICIPANTS: A 6-month randomized, double-blind, placebo-controlled trial in 21 healthy elderly men aged 65-75 yr, was performed. Participants were randomized to receive placebo GH and placebo T, rhGH and placebo T (GH), T and placebo GH (T), or rhGH and T (GHT). INTERVENTIONS: The leucine rate of appearance (index of proteolysis), nonoxidative leucine disposal rate (an index of protein synthesis), and leucine oxidation rate were measured with an infusion of l-[1-(13)C] leucine. Muscle biopsies for the measurement of gene expression were performed. Body composition and aerobic capacity (maximal oxygen capacity) were measured. RESULTS: Serum IGF-I levels increased significantly with GH and GHT (P < 0.001) compared with placebo. T increased significantly only in the T group (P = 0.028). Leucine rate of appearance and nonoxidative leucine disposal rate increased with GH (P = 0.015, P = 0.019) and GHT (P = 0.017, P = 0.02), but leucine oxidation did not change significantly in any treatment group. Midthigh muscle mass and maximal oxygen capacity increased (P < 0.04) with GHT only. Expression of muscle function genes did not change significantly, but the within-group comparisons revealed a significant increase of androgen receptor expression in the GHT group (P = 0.001). CONCLUSION: This study showed that 6-month treatment with low-dose GH alone or with T in healthy elderly men produces comparable increments in whole body protein turnover and protein synthesis.
Authors: Kimberly T Brill; Arthur L Weltman; Angela Gentili; James T Patrie; David A Fryburg; John B Hanks; Randall J Urban; Johannes D Veldhuis Journal: J Clin Endocrinol Metab Date: 2002-12 Impact factor: 5.958
Authors: Marc R Blackman; John D Sorkin; Thomas Münzer; Michele F Bellantoni; Jan Busby-Whitehead; Thomas E Stevens; Jocelyn Jayme; Kieran G O'Connor; Colleen Christmas; Jordan D Tobin; Kerry J Stewart; Ernest Cottrell; Carol St Clair; Katharine M Pabst; S Mitchell Harman Journal: JAMA Date: 2002-11-13 Impact factor: 56.272
Authors: M M Bamman; J R Shipp; J Jiang; B A Gower; G R Hunter; A Goodman; C L McLafferty; R J Urban Journal: Am J Physiol Endocrinol Metab Date: 2001-03 Impact factor: 4.310
Authors: Arny A Ferrando; Melinda Sheffield-Moore; Catherine W Yeckel; Charles Gilkison; Jie Jiang; Alison Achacosa; Steven A Lieberman; Kevin Tipton; Robert R Wolfe; Randall J Urban Journal: Am J Physiol Endocrinol Metab Date: 2002-03 Impact factor: 4.310
Authors: Stephen Welle; Kirti Bhatt; Bharati Shah; Nancy Needler; Joseph M Delehanty; Charles A Thornton Journal: J Appl Physiol (1985) Date: 2002-12-20
Authors: Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen Journal: Endocr Rev Date: 2012-03-20 Impact factor: 19.871
Authors: Dmitry A Sakharov; Diana V Maltseva; Evgeniy A Riabenko; Maxim U Shkurnikov; Hinnak Northoff; Alexander G Tonevitsky; Anatoly I Grigoriev Journal: Eur J Appl Physiol Date: 2011-06-30 Impact factor: 3.078
Authors: Wm C Chumlea; M Cesari; W J Evans; L Ferrucci; R A Fielding; M Pahor; S Studenski; B Vellas Journal: J Nutr Health Aging Date: 2011-06 Impact factor: 4.075
Authors: Kevin E Yarasheski; Carmen Castaneda-Sceppa; Jiaxiu He; Miwa Kawakubo; Shalender Bhasin; Ellen F Binder; E Todd Schroeder; Ronenn Roubenoff; Stan P Azen; Fred R Sattler Journal: Am J Clin Nutr Date: 2011-05-04 Impact factor: 7.045
Authors: Gregory C Henderson; Ketan Dhatariya; G Charles Ford; Katherine A Klaus; Rita Basu; Robert A Rizza; Michael D Jensen; Sundeep Khosla; Peter O'Brien; K Sreekumaran Nair Journal: FASEB J Date: 2008-09-30 Impact factor: 5.191